{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:46:20Z","timestamp":1792784780785,"version":"4.5.0"},"reference-count":0,"publisher":"American Society of Hematology","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1182\/bloodadvances.2026021323","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:03:08Z","timestamp":1792782188000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Feasibility of Reduced-Frequency Dosing of Axatilimab in Patients Treated in the AGAVE-201 Study"],"prefix":"10.1182","author":[{"given":"Nosha","family":"Farhadfar","sequence":"first","affiliation":[{"name":"Sarah Cannon Transplant & Cellular Therapy Program, Methodist Hospital, San Antonio, Texas, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sola Soto","sequence":"additional","affiliation":[{"name":"Hospital Universitario Vall d'Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[{"name":"Mayo Clinic Arizona, Phoenix, Arizona, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valkal","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, Delaware, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Helen","family":"Andersen","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, Delaware, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyi","family":"Xue","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, Delaware, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,23]]},"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026021323\/2596829\/bloodadvances.2026021323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026021323\/2596829\/bloodadvances.2026021323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:03:08Z","timestamp":1792782188000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/doi\/10.1182\/bloodadvances.2026021323\/571688\/Safety-and-Feasibility-of-Reduced-Frequency-Dosing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026021323","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"article-number":"bloodadvances.2026021323"}}